Ftse Mib
35.355,87
0,58%
DAX
18.869,36
0,78%
S&P 500
5.308,15
1,17%
NASDAQ
16.742,39
1,40%
Bitcoin
66.048,20
7,31%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ FibroGen Inc (FGEN) FibroGen Inc (FGEN) Notizie

FGEN

FibroGen (FGEN)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:FGEN
DataOraFonteTitoloSimboloCompagnia
07/05/202417:55AllPennyStocks.comTraders Rush To Buy Biotech Following Q1 Earnings BeatNASDAQ:FGENFibroGen Inc
07/05/202413:00GlobeNewswire Inc.FibroGen to Participate in Upcoming Investor ConferencesNASDAQ:FGENFibroGen Inc
06/05/202422:10Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:FGENFibroGen Inc
06/05/202422:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:FGENFibroGen Inc
06/05/202422:02GlobeNewswire Inc.FibroGen Reports First Quarter 2024 Financial ResultsNASDAQ:FGENFibroGen Inc
29/04/202413:00GlobeNewswire Inc.FibroGen to Report First Quarter 2024 Financial ResultsNASDAQ:FGENFibroGen Inc
24/04/202422:02GlobeNewswire Inc.FibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer will be Presented at the 2024 American Society of Clinical Oncology ANASDAQ:FGENFibroGen Inc
02/04/202423:46GlobeNewswire Inc.FibroGen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate CancerNASDAQ:FGENFibroGen Inc
26/03/202412:00GlobeNewswire Inc.FibroGen to Present at 23rd Annual Needham Virtual Healthcare ConferenceNASDAQ:FGENFibroGen Inc
11/03/202412:00GlobeNewswire Inc.FibroGen Appoints Deyaa Adib, M.D. as Chief Medical OfficerNASDAQ:FGENFibroGen Inc
09/03/202401:19Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FGENFibroGen Inc
26/02/202422:06GlobeNewswire Inc.FibroGen Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:FGENFibroGen Inc
26/02/202422:05GlobeNewswire Inc.FibroGen Regains All Rights to Roxadustat from AstraZeneca in the United States and Other AstraZeneca Territories, Except China and South KoreaNASDAQ:FGENFibroGen Inc
20/02/202413:00GlobeNewswire Inc.FibroGen to Report Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:FGENFibroGen Inc
14/02/202421:37Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:FGENFibroGen Inc
05/02/202413:00GlobeNewswire Inc.FibroGen To Host Part I of Virtual KOL Investor Event Series to Review Pamrevlumab Clinical Program in Pancreatic Cancer on February 13, 2024NASDAQ:FGENFibroGen Inc
25/01/202413:00GlobeNewswire Inc.FibroGen Announces Completion of the Pamrevlumab Arm in Precision Promise, Pancreatic Cancer Action Network’s Phase 2/3 Adaptive Platform Trial for Metastatic Pancreatic CancerNASDAQ:FGENFibroGen Inc
09/12/202323:02GlobeNewswire Inc.FibroGen Presents Data from Phase 3 MATTERHORN Trial of Roxadustat in Patients with Anemia of Lower Risk Transfusion-Dependent Myelodysplastic Syndromes at American Society of Hematology Annual MeetingNASDAQ:FGENFibroGen Inc
06/11/202322:01GlobeNewswire Inc.FibroGen Reports Third Quarter 2023 Financial ResultsNASDAQ:FGENFibroGen Inc
23/10/202313:00GlobeNewswire Inc.FibroGen to Report Third Quarter 2023 Financial ResultsNASDAQ:FGENFibroGen Inc
01/09/202323:31Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:FGENFibroGen Inc
29/08/202322:15GlobeNewswire Inc.FibroGen Announces Topline Results from LELANTOS-2, a Phase 3 Clinical Study of Pamrevlumab in Ambulatory Duchenne Muscular DystrophyNASDAQ:FGENFibroGen Inc
07/08/202322:22Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:FGENFibroGen Inc
07/08/202322:01GlobeNewswire Inc.FibroGen Reports Second Quarter 2023 Financial ResultsNASDAQ:FGENFibroGen Inc
25/07/202313:00GlobeNewswire Inc.FibroGen Announces Leadership TransitionNASDAQ:FGENFibroGen Inc
24/07/202313:00GlobeNewswire Inc.FibroGen to Report Second Quarter 2023 Financial ResultsNASDAQ:FGENFibroGen Inc
26/06/202322:28Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:FGENFibroGen Inc
26/06/202315:06Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:FGENFibroGen Inc
26/06/202313:04GlobeNewswire Inc.FibroGen Announces Topline Results from Phase 3 ZEPHYRUS-1 Study of Pamrevlumab for the Treatment of Idiopathic Pulmonary FibrosisNASDAQ:FGENFibroGen Inc
08/06/202323:52Edgar (US Regulatory)Report of Proposed Sale of Securities (144)NASDAQ:FGENFibroGen Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:FGEN

La tua Cronologia

COIN
OTBCETH
Outside the Box Coin
IDCM
TXCETH
Tripxchain
CRTO
ETHBTC
Ethereum
LSE
0QXO
Snowbird
OKEX
KSMUSDT
Kusama
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network